Latest Ucb S A (UCBJF) Headlines UCB Misses Earni
Post# of 3
UCB Misses Earnings Ests, Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 12:32PM CST
UCB reported 2013 earnings per share of $2.56, missed the Zacks Consensus Estimate of $2.84.
UCB : CONVENING NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
Thomson Reuters ONE - Fri Feb 21, 2:01AM CST
The shareholders are invited to attend the Extraordinary General Meeting which will be held on Monday, 24 March 2014, at 09:00 am CET at the registered office of UCB SA/NV, Allee de la Recherche 60 - 1070 Brussels, for the purpose of considering the items shown on the agenda set out below.
Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine
CHMP Positive on Roche's RoActemra's Subcutaneous Formulation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 9:50AM CST
Roche recently received positive news when the Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion on the subcutaneous formulation of rheumatoid arthritis (RA) drug RoActemra.
Good News for Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 22, 12:30PM CDT
Roche received encouraging news when the U.S. Food and Drug Administration (FDA) approved a subcutaneous (SC) formulation of its rheumatoid arthritis (RA) drug Actemra
Loss Narrows at Immunomedics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 26, 8:54AM CDT
Immunomedics reported fourth quarter 2013 loss of 9 cents per share.
Good News for RedHill Biopharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 23, 3:10PM CDT
Good news flowed in at RedHill Biopharma when the company received a positive feedback on its RHB-104.
Another Generic Launch at Mylan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 16, 9:50AM CDT
Mylan launched its generic version of Abbott Labs' Trilipix.
New Data on UCB's Cimzia - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 14, 2:48PM CDT
UCB presented new data from the RAPID-PsA study and RAPID-axSpA study on Cimzia at the European League Against Rheumatism (EULAR) Congress.
Update on UCB Lupus Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 13, 8:40PM CDT
UCB recently presented new data on its lupus candidate, epratuzumab, from an open-label extension study of the EMBLEM phase IIb study
Label Expansion for Roche's RoActemra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 12, 9:10PM CDT
Roche announced that it obtained European Medicines Agency (EMA) approval for the label expansion of its rheumatoid arthritis (RA) drug RoActemra.
Data on UCB's Neupro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 22, 8:55PM CDT
UCB presented data from a study showing the effect of Neupro on cardiovascular measures in patients with restless legs syndrome.
Nektar Posts Wider Loss, Maintains View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 15, 10:26AM CDT
Nektar reported a loss of 48 cents per share in the first quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 41 cents.
Questcor Misses on Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 03, 1:16PM CDT
Questcor reported first quarter 2013 adjusted earnings per share of 66 cents, up 13.8% from the year-ago period
Valeant Beats Earnings, Misses Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 03, 12:05PM CDT
Valeant Pharmaceuticals' (VRX) first quarter 2013 earnings of $1.27 (excluding special items but including stock-based compensation expense) were short of the Zacks Consensus Estimate by a penny but were up from the year-ago earnings of 1.08 per share